FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Beth Karlan

Research Profile

Disorders

Genes & Molecular Sequences

Concepts & Ideas

Physiology

Chemicals & Drugs

Anatomy

Tumor Cell Line

Procedures

Co-author Network

Publications

TOP 3
Elena S Diaz; Beth Y Karlan; Andrew J Li
Obesity-associated adipokines correlate with survival in epithelial ovarian cancer.
C Bethan Powell; E M Swisher; Ilana Cass; R L Garcia; Beth Y Karlan; J Lester; J McLennan; B Norquist; L Chen
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
De-Chen Lin; Li-Zhen Liu; Paresma Patel; Jonathan W Said; Michèl Schummer; Arjun Sharma; Hongmao Sun; Patrick Tan; Craig J Thomas; Nicole Urban; Jay Vadgama; Martin Walsh; Liang Xu; Henry Yang; Dong Yin; Daniel Chan; Ling-Wen Ding; Ngan Doan; Beth Y Karlan; Jenny Lester; H Phillip Koeffler
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Beth Karlan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Elena S Diaz; Beth Y Karlan; Andrew J Li
Obesity-associated adipokines correlate with survival in epithelial ovarian cancer.
Gynecologic oncology 2013;129(2):353-7.
2013: C Bethan Powell; E M Swisher; Ilana Cass; R L Garcia; Beth Y Karlan; J Lester; J McLennan; B Norquist; L Chen
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
Gynecologic oncology 2013;129(2):364-71.
2013: De-Chen Lin; Li-Zhen Liu; Paresma Patel; Jonathan W Said; Michèl Schummer; Arjun Sharma; Hongmao Sun; Patrick Tan; Craig J Thomas; Nicole Urban; Jay Vadgama; Martin Walsh; Liang Xu; Henry Yang; Dong Yin; Daniel Chan; Ling-Wen Ding; Ngan Doan; Beth Y Karlan; Jenny Lester; H Phillip Koeffler
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(15):6109-14.
2012: Nicole Urban; Mary B Daly; Beth Y Karlan; Martin W McIntosh; Pamela J Paley; Melanie R Palomares; Jason Thorpe; Charles W Drescher
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(11):2087-94.
2012: Elena S Diaz; Beth Y Karlan; Andrew J Li
Impact of beta blockers on epithelial ovarian cancer survival.
Gynecologic oncology 2012;127(2):375-8.
2012: Elizabeth M Swisher; Toshiyasu Taniguchi; Beth Y Karlan
Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time.
Journal of the National Cancer Institute 2012;104(9):642-5.
2012: Jian-Feng Lu; Rebeca Melara; Lynn Navale; Erik Rasmussen; Daniel E Stepan; Beth Y Karlan; Mita Kuchimanchi; Ignace B Vergote; David M Weinreich; Yu-Nien Sun
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Cancer chemotherapy and pharmacology 2012;69(5):1135-44.
2012: Stan B Kaye; Elizabeth S Lowe; Jan Lubinski; Ursula Matulonis; Tamar Safra; Ignace Vergote; Mark Wickens; Amit Amnon; Joo Ern Ang; Katherine M Bell-McGuinn; James Carmichael; Lee-May Chen; Michael Friedlander; Charlie Gourley; Beth Y Karlan; Bella Kaufman
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(4):372-9.
2012: Deborah A Zajchowski; Beth Y Karlan; Laura K Shawver
Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Molecular cancer therapeutics 2012;11(2):492-502.
2012: Beth Y Karlan; Charles A Leath; Raj V Nagarkar; Hoa Nguyen; Amit Oza; Charles H Pippitt; Diane M Provencher; Gary E Richardson; Daniel E Stepan; Yu-Nien Sun; Marjan Tassoudji; John V Brown; Martin Buck; Setsuko K Chambers; Allan Covens; Margaret Davy; Prafull Ghatage; Vincent L Hansen; David M Weinreich; Ignace B Vergote
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(4):362-71.
2012: Nicole D Fleming; Beth Y Karlan; Carl W Miller; Hoorig Nassanian; Sandra Orsulic; Hasmik Agadjanian; Christine S Walsh
Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Cancer 2012;118(3):689-97.
2012: Barbie Taylor-Harding; Hasmik Agadjanian; X Guo; Beth Y Karlan; S Kwon; C Miller; Hoorig Nassanian; Sandra Orsulic; Christine S Walsh
Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
British journal of cancer 2012;106(2):333-43.
2012: David A Engler; David M Gershenson; Joe W Gray; Jenny Gross; Whitfield B Growdon; Sumeet Gupta; Beth Y Karlan; Wen-Lin Kuo; Serena F Allred; Michael J Birrer; Michael T Deavers; Ronny I Drapkin; Mai Nitta; Sandra Orsulic; Bo R Rueda; Petra A Sergent; Gayatry Mohapatra
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
PloS one 2012;7(2):e30996.
2011: Dennis S Chi; Deborah K Armstrong; Robert E Bristow; Beth Y Karlan
Is the easier way ever the better way?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(31):4073-5.
2011: Robert N Hoover; Marianne Hyer; Beth Y Karlan; Raymond Kaufman; Kenneth L Noller; Julie R Palmer; Ruth M Pfeiffer; Stanley J Robboy; Robert C Saal; William C Strohsnitter; Linda Titus-Ernstoff; Ervin Adam; Brian Bond; Andrea L Cheville; Theodore Colton; Patricia Hartge; Elizabeth E Hatch; Arthur L Herbst; Rebecca Troisi
Adverse health outcomes in women exposed in utero to diethylstilbestrol.
The New England journal of medicine 2011;365(14):1304-14.
2011: Barbara Norquist; Christopher C Pennil; Wataru Sakai; Rochelle Garcia; Jenny Gross; Beth Y Karlan; Toshiyasu Taniguchi; Kaitlyn A Wurz; Elizabeth M Swisher
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(22):3008-15.
2011: Min Zhu; David D Chang; Judith C Gasson; Beth Y Karlan; Lillian Ramos; Romaine E Saxton; Dennis J Slamon
Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis.
Molecular cancer therapeutics 2011;10(8):1500-8.
2011: Marlena S Fejzo; Chuck Ginther; Judy Dering; Lee Anderson; Natarajan Venkatesan; Gottfried E Konecny; Beth Y Karlan; Dennis J Slamon
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK.
Genes, chromosomes & cancer 2011;50(6):434-41.
2011: Nicole D Fleming; Ilana Cass; Christine S Walsh; Beth Y Karlan; Andrew J Li
CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Gynecologic oncology 2011;121(2):249-52.
2011: Nicole D Fleming; Scott E Lentz; Ilana Cass; Andrew J Li; Beth Y Karlan; Christine S Walsh
Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?
Gynecologic oncology 2011;120(2):189-92.
2010: Barbie Taylor-Harding; Sandra Orsulic; Beth Y Karlan; Andrew J Li
Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Gynecologic oncology 2010;119(3):549-56.
2010: Min Zhu; Marlena S Fejzo; Lee Anderson; Judy Dering; Charles Ginther; Lillian Ramos; Judith C Gasson; Beth Y Karlan; Dennis J Slamon
Periostin promotes ovarian cancer angiogenesis and metastasis.
Gynecologic oncology 2010;119(2):337-44.
2010: Nageatte Ibrahim; Lei He; Chee-Onn Leong; Deyin Xing; Beth Y Karlan; Elizabeth M Swisher; Bo R Rueda; Sandra Orsulic; Leif W Ellisen
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Cancer research 2010;70(18):7155-65.
2010: Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3555-61.
2010: Danielle Vicus; Amy Finch; Barry Rosen; Isabel Fan; Linda Bradley; Ilana Cass; Ping Sun; Beth Y Karlan; John McLaughlin; Steven A Narod
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Gynecologic oncology 2010;118(2):155-9.
2010: Yevgeniya J M Ioffe; R Geoffrey Elmore; Beth Y Karlan; Andrew J Li
Effect of cigarette smoking on epithelial ovarian cancer survival.
The Journal of reproductive medicine 2010;55(7-8):346-50.
2010: Amer Karam; Beth Y Karlan
Ovarian cancer: the duplicity of CA125 measurement.
Nature reviews. Clinical oncology 2010;7(6):335-9.
2010: Aparna A Kamat; Mathew Baldwin; Diana Urbauer; Diana Dang; Liz Y Han; Andrew Godwin; Beth Y Karlan; Joe Simpson; David M Gershenson; Robert L Coleman; Farideh Z Bischoff; Anil K Sood
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
Cancer 2010;116(8):1918-25.
2010: Ilana Cass; Ann Walts; Beth Y Karlan
Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?
Gynecologic oncology 2010;117(1):27-31.
2010: Cheryl Mercado; David S Zingmond; Beth Y Karlan; Evan Sekaris; Jenny Gross; Melinda Maggard-Gibbons; James S Tomlinson; Clifford Y Ko
Quality of care in advanced ovarian cancer: the importance of provider specialty.
Gynecologic oncology 2010;117(1):18-22.
2010: Christine S Walsh; Audra Blum; Ann Walts; Randa Alsabeh; Hang Tran; H Phillip Koeffler; Beth Y Karlan
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.
Gynecologic oncology 2010;116(3):516-21.
2010: Ilana Cass; Beth Y Karlan
Ovarian cancer symptoms speak out--but what are they really saying?
Journal of the National Cancer Institute 2010;102(4):211-2.
2010: Christine S Walsh; Beth Y Karlan
Molecular signatures of ovarian cancer: from detection to prognosis.
Molecular diagnosis & therapy 2010;14(1):13-22.
2010: Nils Thoennissen; James O'Kelly; D Lu; G B Iwanski; D T La; Sam Abbassi; A Leiter; Beth Y Karlan; Rajendra Mehta; H Phillip Koeffler
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Oncogene 2010;29(2):285-96.
2010: Ido Wolf; Y Laitman; Tami Rubinek; L Abramovitz; I Novikov; R Beeri; M Kuro-O; H Phillip Koeffler; Raphael Catane; L S Freedman; E Levy-Lahad; Beth Y Karlan; Eitan Friedman; Bella Kaufman
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Oncogene 2010;29(1):26-33.
2010: Lei Zhang; Hua Xiao; Scott Karlan; Hui Zhou; Jenny Gross; David Elashoff; David Akin; Xinmin Yan; David Chia; Beth Y Karlan; David T Wong
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer.
PloS one 2010;5(12):e15573.
2010: Michèl Schummer; Ann Green; J David Beatty; Beth Y Karlan; Scott Karlan; Jenny Gross; Sean Thornton; Martin McIntosh; Nicole Urban
Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection.
PloS one 2010;5(2):e9122.
2010: Ausra Bendoraite; Emily C Knouf; Kavita S Garg; Rachael K Parkin; Evan M Kroh; Kathy C O'Briant; Aviva P Ventura; Andrew K Godwin; Beth Y Karlan; Charles W Drescher; Nicole Urban; Beatrice S Knudsen; Muneesh Tewari
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.
Gynecologic oncology 2010;116(1):117-25.
2010: Daniel R Scoles; Xuan Xu; Haimei Wang; Hang Tran; Barbie Taylor-Harding; Andrew Li; Beth Y Karlan
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein.
Gynecologic oncology 2010;116(1):109-16.
2010: Andrew J Li; R Geoffrey Elmore; Ida Yii-der Chen; Beth Y Karlan
Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers.
Gynecologic oncology 2010;116(1):78-81.
2010: Andrew J Li; Paula McAllister; Beth Y Karlan
Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
Gynecologic oncology 2010;116(1):105-8.
2009: Y J Ioffe; Andrew J Li; Christine S Walsh; Beth Y Karlan; Ronald S Leuchter; Charles Forscher; Ilana Cass
Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
Gynecologic oncology 2009;115(3):466-71.
2009: Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus V Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
A role for BRCA1 in uterine leiomyosarcoma.
Cancer research 2009;69(21):8231-5.
2009: Amer Karam; Jing Wang Chiang; Ewina Fung; Vladimir Nossov; Beth Y Karlan
Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Gynecologic oncology 2009;114(2):246-52.
2009: Eric Winer; Julie Gralow; Lisa Diller; Beth Y Karlan; Patrick Loehrer; Lori J Pierce; George Demetri; Patricia Anne Ganz; Barnett Kramer; Mark G Kris; Maurie Markman; Robert Mayer; David G Pfister; Derek Raghavan; Scott Ramsey; Gregory Reaman; Howard Sandler; Raymond Sawaya; Lynn Schuchter; John Sweetenham; Linda Vahdat; Richard L Schilsky
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):812-26.
2008: Christine S Walsh; Beth Y Karlan
Lymphadenectomy's role in early endometrial cancer: prognostic or therapeutic?
Journal of the National Cancer Institute 2008;100(23):1660-1.
2008: Christine S Walsh; Seishi Ogawa; Daniel R Scoles; Carl W Miller; Norihiko Kawamata; Steven A Narod; H Phillip Koeffler; Beth Y Karlan
Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7645-51.
2008: Ido Wolf; S Levanon-Cohen; S Bose; H Ligumsky; B Sredni; Hannah Kanety; M Kuro-o; Beth Y Karlan; B Kaufman; H P Koeffler; T Rubinek
Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.
Oncogene 2008;27(56):7094-105.
2008: Andrew J Li; Beth Y Karlan
Androgens and epithelial ovarian cancer: What's the connection?
Cancer biology & therapy 2008;7(11):1712-6.
2008: R Geoffrey Elmore; Yevgeniya Ioffe; Daniel R Scoles; Beth Y Karlan; Andrew J Li
Impact of statin therapy on survival in epithelial ovarian cancer.
Gynecologic oncology 2008;111(1):102-5.
2008: Marlena S Fejzo; Judy Dering; Chuck Ginther; Lee Anderson; Lilian Ramos; Christine Walsh; Beth Y Karlan; Dennis J Slamon
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Genes, chromosomes & cancer 2008;47(10):873-83.
2008: Naoki Wakimoto; Dong Yin; James O'Kelly; Talin Haritunians; Beth Y Karlan; Jonathan Said; Hongtao Xing; H Phillip Koeffler
Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo.
Cancer science 2008;99(9):1793-7.
2008: Steven A Narod; Susan L Neuhausen; G Vichodez; S Armel; Henry T Lynch; Parviz Ghadirian; S Cummings; Olufunmilayo I Olopade; D Stoppa-Lyonnet; Fergus J. Couch; T Wagner; Ellen Warner; William D Foulkes; Howard M Saal; Jeffrey N Weitzel; A Tulman; A Poll; R Nam; P Sun; Jessica Danquah; Susan Domchek; Nadine Tung; Peter Ainsworth; Douglas Horsman; Charmaine Kim-Sing; Christine Maugard; Andrea Eisen; Mary Daly; Wendy McKinnon; Marie Wood; Claudine Isaacs; Dawna Gilchrist; Beth Y Karlan; Raluca Nedelcu; Wendy Meschino; Judy Garber; Barbara Pasini; Siranoush Manoukian; Christina Bellati
Rapid progression of prostate cancer in men with a BRCA2 mutation.
British journal of cancer 2008;99(2):371-4.
2008: James O'Kelly; Alice Chung; Nathan Lemp; Katya Chumakova; Dong Yin; He-Jing Wang; Jonathan Said; Dorina Gui; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
Functional domains of CCN1 (Cyr61) regulate breast cancer progression.
International journal of oncology 2008;33(1):59-67.
2008: Christine S Walsh; Seishi Ogawa; Hisae Karahashi; Daniel R Scoles; James C Pavelka; Hang Tran; Carl W Miller; Norihiko Kawamata; Charles Ginther; Judy Dering; Masashi Sanada; Yasuhito Nannya; Dennis J Slamon; H Phillip Koeffler; Beth Y Karlan
ERCC5 is a novel biomarker of ovarian cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2952-8.
2008: Andrew J Li; Daniel R Scoles; Klara U M Armstrong; Beth Y Karlan
Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas.
Gynecologic oncology 2008;109(2):220-5.
2008: Elizabeth M Swisher; Wataru Sakai; Beth Y Karlan; Kaitlyn Wurz; Nicole Urban; Toshiyasu Taniguchi
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Cancer research 2008;68(8):2581-6.
2008: Beth Y Karlan
Improving efficiencies in translational science.
Gynecologic oncology 2008;108(3):461.
2008: Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J. Couch; Nicole Urban; Toshiyasu Taniguchi
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Nature 2008;451(7182):1116-20.
2007: James C Pavelka; Andrew J Li; Beth Y Karlan
Hereditary ovarian cancer--assessing risk and prevention strategies.
Obstetrics and gynecology clinics of North America 2007;34(4):651-65, vii-viii.
2007: Andrew J Li; R Geoffrey Elmore; James C Pavelka; Beth Y Karlan
Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
Gynecologic oncology 2007;107(3):420-3.
2007: Christine S Walsh; Beth Y Karlan
Contemporary progress in ovarian cancer screening.
Current oncology reports 2007;9(6):485-93.
2007: Johnathan M Lancaster; C Bethan Powell; Noah D Kauff; Ilana Cass; Lee-May Chen; Karen H Lu; David G Mutch; Andrew Berchuck; Beth Y Karlan; Thomas J Herzog
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecologic oncology 2007;107(2):159-62.
2007: Beth Y Karlan
Can lifestyle influence genetics?
Nature clinical practice. Oncology 2007;4(10):555.
2007: Ido Wolf; Shikha Bose; Julian C Desmond; Bryan T Lin; Elizabeth A Williamson; Beth Y Karlan; H Phillip Koeffler
Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.
Breast cancer research and treatment 2007;105(2):139-55.
2007: Joanne Kotsopoulos; Jan Lubinski; Henry T Lynch; Jan Klijn; Parviz Ghadirian; Susan L Neuhausen; Charmaine Kim-Sing; William D Foulkes; Pal Moller; Claudine Isaacs; Susan Domchek; Susan Randall; Kenneth Offit; Nadine Tung; Peter Ainsworth; Ruth Gershoni-Baruch; Andrea Eisen; Mary Daly; Beth Y Karlan; Howard M Saal; Fergus J. Couch; Barbara Pasini; Teresa Wagner; Eitan Friedman; Gad Rennert; Charis Eng; Jeffrey N Weitzel; Ping Sun; steven narod; Judy E Garber; M Osborne; D Fishman; J McLennan; W McKinnon; Sofia D Merajver; H Olsson; D Provencher; B Pasche; G Evans; W S Meschino; E Lemire; A Chudley; D Rayson; C Bellati
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast cancer research and treatment 2007;105(2):221-8.
2007: Beth Y Karlan; Andrew Berchuck; David Mutch
The role of genetic testing for cancer susceptibility in gynecologic practice.
Obstetrics and gynecology 2007;110(1):155-67.
2007: Ido Wolf; James O'Kelly; Naoki Wakimoto; Anh Nguyen; Franck Amblard; Beth Y Karlan; Jack L Arbiser; H Phillip Koeffler
Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.
International journal of oncology 2007;30(6):1529-37.
2007: Joanne Kotsopoulos; Parviz Ghadirian; Ahmed El-Sohemy; Henry T Lynch; Carrie Snyder; Mary Daly; Susan M Domchek; Susan Randall; Beth Y Karlan; Phil Zhang; Shiyu Zhang; Ping Sun; Steven A Narod
The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(5):912-6.
2007: Beth Y Karlan; Martin McIntosh
The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(11):1303-4.
2007: Ido Wolf; Shikha Bose; Elizabeth A Williamson; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
International journal of cancer. Journal international du cancer 2007;120(5):1013-22.
2007: Antonio Santillan-Gomez; Amer Karam; Andrew J Li; Robert L Giuntoli; Ginger J Gardner; Ilana Cass; Beth Y Karlan; Robert E Bristow
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Gynecologic oncology 2007;104(3):686-90.
2007: Christine S Walsh; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Gynecologic oncology 2007;104(3):660-4.
2007: Allison E Axtell; Margaret H Lee; Robert E Bristow; Sean C Dowdy; William A Cliby; Steven Raman; John P Weaver; Mojan Gabbay; Michael Ngo; Scott Lentz; Ilana Cass; Andrew J Li; Beth Y Karlan; Christine H Holschneider
Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(4):384-9.
2007: Amer Karam; Antonio Santillan-Gomez; Robert E Bristow; Robert L Giuntoli; Ginger J Gardner; Ilana Cass; Beth Y Karlan; Andrew J Li
Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
Gynecologic oncology 2007;104(2):377-80.
2007: John R McLaughlin; Harvey A Risch; Jan Lubinski; Pal Moller; Parviz Ghadirian; Henry T Lynch; Beth Y Karlan; David Fishman; Barry Rosen; Susan L Neuhausen; Kenneth Offit; Noah D Kauff; Susan M Domchek; Nadine Tung; Eitan Friedman; William D Foulkes; Ping Sun; Steven A Narod
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
The lancet oncology 2007;8(1):26-34.
2007: Daniel R Scoles; James C Pavelka; Ilana Cass; Hang Tran; Rae Lynn Baldwin; Klara Armstrong; Beth Y Karlan
Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.
Gynecologic oncology 2007;104(1):120-8.
2007: Dimitry L Lerner; Christine S Walsh; Ilana Cass; Beth Y Karlan; Andrew J Li
The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Gynecologic oncology 2007;104(1):91-4.
2006: Jose G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey N Weitzel; Monica Morrow; Barbara L Weber; Francis M Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen B Gruber; Kenneth Offit
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4642-60.
2006: Jose G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey N Weitzel; Monica Morrow; Barbara L Weber; Francis M Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen B Gruber; Kenneth Offit
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Annals of surgical oncology 2006;13(10):1296-321.
2006: James C Pavelka; Rebecca S Brown; Beth Y Karlan; Ilana Cass; Ronald S Leuchter; Leo D Lagasse; Andrew J Li
Effect of obesity on survival in epithelial ovarian cancer.
Cancer 2006;107(7):1520-4.
2006: Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4324-32.
2006: Ido Wolf; James O'Kelly; Tami Rubinek; Min Tong; Anh Nguyen; Bryan T Lin; Hsin-Hsiung Tai; Beth Y Karlan; H Phillip Koeffler
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Cancer research 2006;66(15):7818-23.
2006: Amy Finch; Mario E Beiner; Jan Lubinski; Henry T Lynch; Pal Moller; Barry Rosen; Joan Murphy; Parviz Ghadirian; Eitan Friedman; William D Foulkes; Charmaine Kim-Sing; Teresa Wagner; Nadine Tung; Fergus J. Couch; Dominique Stoppa-Lyonnet; Peter Ainsworth; Mary Daly; Barbara Pasini; Ruth Gershoni-Baruch; Charis Eng; Olufunmilayo I Olopade; Jane McLennan; Beth Y Karlan; Jeffrey N Weitzel; Ping Sun; Steven A Narod
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
JAMA : the journal of the American Medical Association 2006;296(2):185-92.
2006: Beth Y Karlan
Evolution through intelligent design.
Gynecologic oncology 2006;102(1):1-4.
2006: Jing Wang Chiang; Beth Y Karlan; Llana Cass; Rae Lynn Baldwin
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Gynecologic oncology 2006;101(3):403-10.
2006: Susan Wei; Curtis Balch; Henry H Paik; Yoo-Sung Kim; Rae Lynn Baldwin; Sandya Liyanarachchi; Lang Li; Zailong Wang; Joseph C Wan; Ramana V Davuluri; Beth Y Karlan; Gillian Gifford; Robert Brown; Sun Kim; Hui-Ming (Tim) Huang; Kenneth P Nephew
Prognostic DNA methylation biomarkers in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2788-94.
2006: Eitan Friedman; Joanne Kotsopoulos; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; Susan L Neuhausen; Claudine Isaacs; Barbara Weber; William D Foulkes; Pal Moller; Barry Rosen; Charmaine Kim-Sing; Ruth Gershoni-Baruch; Peter Ainsworth; Mary Daly; Nadine Tung; Andrea Eisen; Olufunmilayo I Olopade; Beth Y Karlan; Howard M Saal; Judy E Garber; Gad Rennert; Dawna Gilchrist; Charis Eng; Kenneth Offit; Michael Osborne; Ping Sun; Steven A Narod
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Breast cancer research : BCR 2006;8(2):R15.
2006: Joanne Kotsopoulos; Jan Lubinski; Susan L Neuhausen; Henry T Lynch; Barry Rosen; Peter Ainsworth; Pal Moller; Parviz Ghadirian; Claudine Isaacs; Beth Y Karlan; Ping Sun; Steven A Narod
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Gynecologic oncology 2006;100(1):83-8.
2005: Jennifer A Byrne; Rosemary L Balleine; Marlena Schoenberg Fejzo; Janelle Mercieca; Yoke-Eng Chiew; Yael Livnat; Luke St Heaps; Gregory B Peters; Karen Byth; Beth Y Karlan; Dennis J Slamon; Paul R Harnett; Anna deFazio
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
International journal of cancer. Journal international du cancer 2005;117(6):1049-54.
2005: Andrew J Li; Dimitry L Lerner; Maria-Emily R Gapuzan; Beth Y Karlan
AIB1 polymorphisms predict aggressive ovarian cancer phenotype.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(12):2919-22.
2005: Ilana Cass; Christine H Holschneider; Nandini Datta; Denise Barbuto; Ann E Walts; Beth Y Karlan
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Obstetrics and gynecology 2005;106(6):1327-34.
2005: Andrew J Li; Robert L Giuntoli; Richard Drake; Sharon Young Byun; Francisco Rojas; Denise Barbuto; Nancy Klipfel; Pamela Edmonds; David S Miller; Beth Y Karlan
Ovarian preservation in stage I low-grade endometrial stromal sarcomas.
Obstetrics and gynecology 2005;106(6):1304-8.
2005: Andrew J Li; Beth Y Karlan
Androgen mediation of thrombocytosis in epithelial ovarian cancer biology.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8015-8.
2005: Beth Y Karlan
Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources: Committee on Government Reform United States House of Representatives.
Gynecologic oncology 2005;99(2):257-60.
2005: Christine Walsh; Christine H Holschneider; Yen Hoang; Khai Tieu; Beth Y Karlan; Ilana Cass
Coexisting ovarian malignancy in young women with endometrial cancer.
Obstetrics and gynecology 2005;106(4):693-9.
2005: Christine H Holschneider; Rae Lynn Baldwin; Kiran Tumber; Chisa Aoyama; Beth Y Karlan
The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5756-63.
2005: Joanne Kotsopoulos; Jan Lubinski; Henry T Lynch; Susan L Neuhausen; Parviz Ghadirian; Claudine Isaacs; Barbara Weber; Charmaine Kim-Sing; William D Foulkes; Ruth Gershoni-Baruch; Peter Ainsworth; Eitan Friedman; Mary Daly; Judy E Garber; Beth Y Karlan; Olufunmilayo I Olopade; Nadine Tung; Howard M Saal; Andrea Eisen; Michael Osborne; Håkan Olsson; Dawna Gilchrist; Ping Sun; Steven A Narod
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Cancer causes & control : CCC 2005;16(6):667-74.
2005: John C Elkas; Jonathan S Berek; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan
Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies.
Gynecologic oncology 2005;97(2):685-92.
2005: David B Agus; Michael S Gordon; Charles Taylor; Ronald B Natale; Beth Y Karlan; David S Mendelson; Michael F Press; David E Allison; Mark X Sliwkowski; Gracie Lieberman; Stephen M Kelsey; Gwen Fyfe
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2534-43.
2004: Beth Y Karlan
Profiling the perpetrator.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4663-4.
2004: Beth Y Karlan
The colon is a pelvic organ too: taking the Couric challenge.
Obstetrics and gynecology 2004;104(5 Pt 1):907-9.
2004: Martin W McIntosh; Charles W Drescher; Beth Y Karlan; Nathalie Scholler; Nicole Urban; Karl Erik Hellstrom; Ingegerd Hellstrom
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
Gynecologic oncology 2004;95(1):9-15.
2004: Alexander Liede; Beth Y Karlan; Steven A Narod
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):735-42.
2004: Beth Y Karlan
Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis.
Gynecologic oncology 2004;92(2):519-20.
2004: Andrew J Li; Alison C Madden; Ilana Cass; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan
The prognostic significance of thrombocytosis in epithelial ovarian carcinoma.
Gynecologic oncology 2004;92(1):211-4.
2003: L-M Chen; S D Yamada; YS Fu; R L Baldwin; Beth Y Karlan
Molecular similarities between primary peritoneal and primary ovarian carcinomas.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):749-55.
2003: Andrew J Li; Rae Lynn Baldwin; Beth Y Karlan
Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3667-73.
2003: Nicole Urban; Martin W McIntosh; Marin Andersen; Beth Y Karlan
Ovarian cancer screening.
Hematology/oncology clinics of North America 2003;17(4):989-1005, ix.
2003: Andrew J Li; Beth Y Karlan
Surgical advances in the treatment of ovarian cancer.
Hematology/oncology clinics of North America 2003;17(4):945-56.
2003: Andrew J Li; Rae Lynn Baldwin; Beth Y Karlan
Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures.
American journal of obstetrics and gynecology 2003;189(1):22-7.
2003: Francesmary Modugno; Roxana Moslehi; Roberta B Ness; Deborah Brooks Nelson; Steven H Belle; Jeffrey A Kant; James E Wheeler; Aimee Wonderlick; David Fishman; Beth Y Karlan; Harvey A Risch; Daniel W Cramer; Marie-Pierre Dube; Steven A Narod
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).
Cancer causes & control : CCC 2003;14(5):439-46.
2003: Ilana Cass; Rae Lynn Baldwin; Taz Varkey; Roxana Moslehi; Steven A Narod; Beth Y Karlan
Improved survival in women with BRCA-associated ovarian carcinoma.
Cancer 2003;97(9):2187-95.
2003: Rae Lynn Baldwin; Hang Tran; Beth Y Karlan
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Cancer research 2003;63(6):1413-9.
2003: M Jane Arboleda; John F Lyons; Fairooz Kabbinavar; Mark R Bray; Bryan E Snow; Raul Ayala; Mordechai Danino; Beth Y Karlan; Dennis J Slamon
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
Cancer research 2003;63(1):196-206.
2002: John C Elkas; Rae Lynn Baldwin; Mark D Pegram; Yiou Tseng; Dennis J Slamon; Beth Y Karlan
A human ovarian carcinoma murine xenograft model useful for preclinical trials.
Gynecologic oncology 2002;87(2):200-6.
2002: Lindsay Gillan; Daniela Matei; David A Fishman; C S Gerbin; Beth Y Karlan; David D Chang
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.
Cancer research 2002;62(18):5358-64.
2002: Daniela Matei; Thomas G Graeber; Rae Lynn Baldwin; Beth Y Karlan; Jianyu Rao; David D Chang
Gene expression in epithelial ovarian carcinoma.
Oncogene 2002;21(41):6289-98.
2002: Sanaz Memarzadeh; Christine H Holschneider; Robert E Bristow; N L Jones; YS Fu; Beth Y Karlan; Jonathan S Berek; Robin Farias-Eisner
FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(5):454-8.
2002: Richard E Buller; Mark S Shahin; Jo Ann Horowitz; Ingo B Runnebaum; Vikas Mahavni; Stan Petrauskas; Rolf Kreienberg; Beth Y Karlan; Dennis J Slamon; Mark D Pegram
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Cancer gene therapy 2002;9(7):567-72.
2002: Richard E Buller; Ingo B Runnebaum; Beth Y Karlan; Jo Ann Horowitz; Mark S Shahin; Thomas E Buekers; Stan Petrauskas; Rolf Kreienberg; Dennis J Slamon; Mark D Pegram
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Cancer gene therapy 2002;9(7):553-66.
2002: Alexander Liede; Beth Y Karlan; Rae Lynn Baldwin; Lawrence D Platt; Graciela Kuperstein; Steven A Narod
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1570-7.
2002: Jing Wang; Andrew J Li; Beth Y Karlan
Chemotherapy in epithelial ovarian cancer.
Current women's health reports 2002;2(1):20-6.
2002: Martin W McIntosh; Nicole Urban; Beth Y Karlan
Generating longitudinal screening algorithms using novel biomarkers for disease.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(2):159-66.
2001: Ingo B Runnebaum; Shan Wang-Gohrke; Danny Vesprini; Rolf Kreienberg; Henry T Lynch; Roxana Moslehi; Parviz Ghadirian; Barbara Weber; Andrew K Godwin; Harvey A Risch; Judy E Garber; C Lerman; Olufunmilayo I Olopade; William D Foulkes; Beth Y Karlan; Ellen Warner; Barry Rosen; Timothy R Rebbeck; P Tonin; M P Dubé; Dirk G Kieback; Steven A Narod
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Pharmacogenetics 2001;11(7):635-8.
2001: Ilana Cass; Rae Lynn Baldwin; E Fasylova; Abbie L Fields; H P Klinger; Carolyn D Runowicz; Beth Y Karlan
Allelotype of papillary serous peritoneal carcinomas.
Gynecologic oncology 2001;82(1):69-76.
2001: Steven A Narod; Ping Sun; Parviz Ghadirian; Henry T Lynch; Claudine Isaacs; Judy E Garber; Barbara Weber; Beth Y Karlan; David Fishman; Barry Rosen; Nadine Tung; Susan L Neuhausen
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Lancet 2001;357(9267):1467-70.
2001: Ilana Cass; Andrew J Li; Carolyn D Runowicz; Abbie L Fields; Gary L Goldberg; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan
Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas.
Gynecologic oncology 2001;80(1):56-61.
2001: A J Li; Beth Y Karlan
Genetic factors in ovarian carcinoma.
Current oncology reports 2001;3(1):27-32.
2000: R S Ismail; Rae Lynn Baldwin; J Fang; Damaris Browning; Beth Y Karlan; Judith C Gasson; David D Chang
Differential gene expression between normal and tumor-derived ovarian epithelial cells.
Cancer research 2000;60(23):6744-9.
2000: John V Brown; William A Peters; Mark A Rettenmaier; Beth Y Karlan; R A Dillman; Michael R Smith; Charles W Drescher; John P Micha
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
Gynecologic oncology 2000;79(3):495-8.
2000: C Crump; Martin W McIntosh; Nicole Urban; G Anderson; Beth Y Karlan
Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(10):1107-11.
2000: Rae Lynn Baldwin; E Nemeth; Hang Tran; H Shvartsman; Ilana Cass; Steven A Narod; Beth Y Karlan
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Cancer research 2000;60(19):5329-33.
2000: L M Chen; Beth Y Karlan
Recurrent ovarian carcinoma: is there a place for surgery?
Seminars in surgical oncology 2000;19(1):62-8.
2000: L M Chen; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan
Splenectomy and surgical cytoreduction for ovarian cancer.
Gynecologic oncology 2000;77(3):362-8.
2000: Roxana Moslehi; W Chu; Beth Y Karlan; David Fishman; Harvey A Risch; A Fields; David Smotkin; Yaacov Ben David; Joseph D Rosenblatt; D Russo; P Schwartz; Nadine Tung; Ellen Warner; Barry Rosen; J Friedman; Jean-Sebastien Brunet; Steven A Narod
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
American journal of human genetics 2000;66(4):1259-72.
1999: Michèl Schummer; Wailap Victor Ng; Roger Bumgarner; Peter S Nelson; B Schummer; D W Bednarski; L Hassell; R L Baldwin; Beth Y Karlan; Leroy Hood
Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.
Gene 1999;238(2):375-85.
1999: S D Yamada; Rae Lynn Baldwin; Beth Y Karlan
Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
Gynecologic oncology 1999;75(1):72-7.
1999: Ilana Cass; Rae Lynn Baldwin; Beth Y Karlan
Molecular advances in gynecologic oncology.
Current opinion in oncology 1999;11(5):394-400.
1999: R L Baldwin; H Tran; Beth Y Karlan
Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis.
Gynecologic oncology 1999;74(2):265-71.
1999: Beth Y Karlan; Rae Lynn Baldwin; E Lopez-Luevanos; Leslie J Raffel; Denise Barbuto; Steven A Narod; Lawrence D Platt
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
American journal of obstetrics and gynecology 1999;180(4):917-28.
1999: Robert E Bristow; F J Montz; Leo D Lagasse; Ronald S Leuchter; Beth Y Karlan
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Gynecologic oncology 1999;72(3):278-87.
1999: Robert E Bristow; Rae Lynn Baldwin; S D Yamada; M Korc; Beth Y Karlan
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Cancer 1999;85(3):658-68.
1999: Cindy A Wilson; L Ramos; M R Villaseñor; K H Anders; M F Press; K Clarke; Beth Y Karlan; J J Chen; Ralph Scully; D Livingston; R H Zuch; M H Kanter; S Cohen; Frank J Calzone; Dennis J Slamon
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Nature genetics 1999;21(2):236-40.
1998: Philippe Descamps; Eric Fondrinier; Florence Biquard; C Binelli; C Lepinard; D Loisel; G Crvencowitcz; L D Platt; Beth Y Karlan
[Is ultrasound screening for ovarian cancer possible in 1998?].
Journal de gynécologie, obstétrique et biologie de la reproduction 1998;27(5):476-81.
1998: JL Abrahamson; Roxana Moslehi; Danny Vesprini; Beth Y Karlan; David Fishman; David Smotkin; Yaacov Ben David; H Biran; A Fields; Jean-Sebastien Brunet; Steven A Narod
No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews.
Cancer research 1998;58(14):2919-22.
1998: L M Chen; Beth Y Karlan
Early detection and risk reduction for familial gynecologic cancers.
Clinical obstetrics and gynecology 1998;41(1):200-14.
1997: M Amir; M M Shabot; Beth Y Karlan
Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications.
American journal of obstetrics and gynecology 1997;176(6):1389-93.
1997: Beth Y Karlan
The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma.
Cancer investigation 1997;15(3):265-9.
1997: Tobias Grote; L F Pineda; R A Figlin; Kelly Pendergrass; Paul J Hesketh; Beth Y Karlan; J A Reeves; L L Porter; C R Benedict; WF Hahne
Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
The cancer journal from Scientific American 1997;3(1):45-51.
1996: W L Ng; Michèl Schummer; F D Cirisano; R L Baldwin; Beth Y Karlan; Leroy Hood
High-throughput plasmid mini preparations facilitated by micro-mixing.
Nucleic acids research 1996;24(24):5045-7.
1996: Robert E Bristow; Leo D Lagasse; Beth Y Karlan
Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.
Cancer 1996;78(10):2049-62.
1996: Graham Casey; Martha E Lopez; Juan Carlos Ramos; S J Plummer; M J Arboleda; M Shaughnessy; Beth Y Karlan; Dennis J Slamon
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Oncogene 1996;13(9):1971-81.
1996: Robert E Bristow; Beth Y Karlan
Ovulation induction, infertility, and ovarian cancer risk.
Fertility and sterility 1996;66(4):499-507.
1996: Y B Kim; D Barbuto; Leo D Lagasse; Beth Y Karlan
Successful treatment of neuroendocrine small cell carcinoma of the cervix metastatic to regional lymph nodes.
Gynecologic oncology 1996;62(3):411-4.
1996: F D Cirisano; Beth Y Karlan
The role of the HER-2/neu oncogene in gynecologic cancers.
Journal of the Society for Gynecologic Investigation 1996;3(3):99-105.
1996: A C Casey; R Farias-Eisner; A L Pisani; F D Cirisano; Y B Kim; L Muderspach; R Futoran; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan
What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995?
Gynecologic oncology 1996;60(3):454-61.
1996: G Crvenkovic; Beth Y Karlan; L D Platt
Current role of ultrasound in ovarian cancer screening.
Clinical obstetrics and gynecology 1996;39(1):259-67.
1996: Robert E Bristow; Beth Y Karlan
The risk of ovarian cancer after treatment for infertility.
Current opinion in obstetrics & gynecology 1996;8(1):32-7.
1995: Beth Y Karlan
Where are we now and where are we going?
Gynecologic oncology 1995;59(3):315-7.
1995: Beth Y Karlan; L D Platt
Ovarian cancer screening. The role of ultrasound in early detection.
Cancer 1995;76(10 Suppl):2011-5.
1995: Beth Y Karlan; R L Baldwin; F D Cirisano; P W Mamula; J Jones; Leo D Lagasse
Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation.
Gynecologic oncology 1995;59(1):67-74.
1995: Beth Y Karlan; J Jones; M Greenwald; Leo D Lagasse
Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro.
American journal of obstetrics and gynecology 1995;173(1):97-104.
1995: P Cane; C Azen; E Lopez; Lawrence D Platt; Beth Y Karlan
Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Gynecologic oncology 1995;57(2):240-5.
1995: A L Pisani; D A Barbuto; D Chen; L Ramos; Leo D Lagasse; Beth Y Karlan
HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
Obstetrics and gynecology 1995;85(5 Pt 1):729-34.
1995: Beth Y Karlan
Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials?
Journal of cellular biochemistry. Supplement 1995;23():227-32.
1994: Beth Y Karlan; Lawrence D Platt
The current status of ultrasound and color Doppler imaging in screening for ovarian cancer.
Gynecologic oncology 1994;55(3 Pt 2):S28-33.
1994: J Jones; Leo D Lagasse; Beth Y Karlan
Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
Gynecologic oncology 1994;55(3 Pt 1):421-6.
1994: Beth Y Karlan; R Marrs; Leo D Lagasse
Advanced-stage ovarian carcinoma presenting during infertility evaluation.
American journal of obstetrics and gynecology 1994;171(5):1377-8.
1994: K F McGonigle; Beth Y Karlan; D A Barbuto; Ronald S Leuchter; Leo D Lagasse; HL Judd
Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
Gynecologic oncology 1994;55(1):126-32.
1994: R Farias-Eisner; F Teng; M Oliveira; Ronald S Leuchter; Beth Y Karlan; Leo D Lagasse; Jonathan S Berek
The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery.
Gynecologic oncology 1994;55(1):108-10.
1994: R Farias-Eisner; F D Cirisano; D Grouse; Ronald S Leuchter; Beth Y Karlan; Leo D Lagasse; Jonathan S Berek
Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease.
Gynecologic oncology 1994;53(1):55-8.
1994: Beth Y Karlan; J Jones; Dennis J Slamon; Leo D Lagasse
Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
Gynecologic oncology 1994;53(1):70-7.
1994: Beth Y Karlan; D Krakow
Genetic aspects of ovarian cancer.
Current opinion in obstetrics & gynecology 1994;6(1):105-10.
1993: Beth Y Karlan; R Hawkins; Carl K Hoh; M Lee; N Tse; P Cane; J Glaspy
Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.
Gynecologic oncology 1993;51(2):175-81.
1993: Beth Y Karlan; L J Raffel; G Crvenkovic; C Smrt; M D Chen; E Lopez; C A Walla; C Garber; P Cane; D A Sarti
A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results.
American journal of obstetrics and gynecology 1993;169(3):494-501.
1993: F D Cirisano; jeffrey greenspoon; R Stenson; R Farias-Eisner; Beth Y Karlan; Leo D Lagasse
The etiology and management of diarrhea in the gynecologic oncology patient.
Gynecologic oncology 1993;50(1):45-8.
1993: Beth Y Karlan; Carl K Hoh; N Tse; R Futoran; R Hawkins; J Glaspy
Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube.
Gynecologic oncology 1993;49(3):383-8.
1993: J V Brown; Beth Y Karlan; jeffrey greenspoon; M H Rosove; Leo D Lagasse
Perioperative coagulopathy in patients undergoing primary cytoreduction.
Cancer 1993;71(8):2557-61.
1993: K F McGonigle; L D Lagasse; Beth Y Karlan
Ovarian, uterine, and cervical cancer in the elderly woman.
Clinics in geriatric medicine 1993;9(1):115-30.
1991: E L Trimble; Beth Y Karlan; L D Lagasse; William J Hoskins
Diagnosing the correct ovarian cancer syndrome.
Obstetrics and gynecology 1991;78(6):1023-6.
1989: Beth Y Karlan; J A Rivero; M E Crabtree; B A Littlefield
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Molecular endocrinology (Baltimore, Md.) 1989;3(6):1006-13.
1989: V Band; Beth Y Karlan; V R Zurawski; B A Littlefield
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Journal of cellular physiology 1989;138(1):106-14.
1988: Beth Y Karlan; W Amin; V Band; V R Zurawski; B A Littlefield
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Gynecologic oncology 1988;31(1):103-12.
1988: Beth Y Karlan; W Amin; S E Casper; B A Littlefield
Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids.
Cancer research 1988;48(12):3502-6.
1987: W Amin; Beth Y Karlan; B A Littlefield
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Cancer research 1987;47(22):6040-5.
1987: Beth Y Karlan; A S Clark; B A Littlefield
A highly sensitive chromogenic microtiter plate assay for plasminogen activators which quantitatively discriminates between the urokinase and tissue-type activators.
Biochemical and biophysical research communications 1987;142(1):147-54.